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Summary 
Nitric  oxide  (NO)  is  an  important  inflammatory mediator in  nonhuman  animal  models  of 
rheumatoid arthritis (RA). The purpose of the present study was to determine whether blood 
mononuclear cells from patients with active RA (as compared to control subjects) have higher 
levels of NO synthase type 2 (NOS2) and produce more NO in vitro. Leukocytes from 25 RA 
patients and 20 normal subjects were examined. Arthritis  activity was assessed  by tender and 
swollen joint counts,  duration  of morning stiffness,  patient assessment of pain,  physician and 
patient global assessment of disease  activity, the modified Stanford Health Assessment Ques- 
tionnaire,  and by blood levels of acute phase reactants. Blood mononuclear cell NOS enzyme 
activity/antigen content and nitrite/nitrate formation in vitro were measured. Blood mononu- 
clear cells from RA patients had increased NOS activity and increased NOS2 antigen content 
as compared to those from normal subjects, and responded to interferon-'y with increased NOS 
expression  and  nitrite/nitrate  production  in  vitro.  NOS  activity  of freshly  isolated  blood 
mononuclear cells correlated significantly with disease  activity, as assessed by tender and swol- 
len joint counts.  Our results demonstrate that patients with RA have systemic activation for 
NOS2  expression, and that the degree of activation correlates with disease activity. Increased 
NOS2 expression and NO generation may be important in the pathogenesis of RA. 
R 
heumatoid arthritis (RA) is a chronic systemic disease 
of unknown etiology that is characterized by joint in- 
flammation  and  progressive  loss  of articular  cartilage  and 
subchondral bone (1). Prominent pathologic features of  joint 
inflammation  are  synovial proliferation  and  mononuclear 
cell infiltration, which are believed to result from dysregu- 
lated production of cytokines, growth factors, cell adhesion 
molecules,  and nonprotein  mediators,  such  as arachidonic 
acid metabolites and reactive oxygen species (2-4). 
Nitric oxide (NO) may be a critical mediator in this in- 
flammatory cascade (5,  6).  NO  is generated endogenously 
from L-arginine by oxidation to L-citrulline and NO.  This 
reaction is catalyzed by a group of three related NO  syn- 
thase  (NOS)  enzymes that  are  encoded  by separate genes 
(neural NOS  [NOS1],  endothelial  NOS  [NOS3],  and in- 
ducible  NOS  or NOS  type 2  [NOS2]).  Increased NOS2 
expression  and  NO  production  have  been  noted  in  in- 
duced and spontaneous nonhuman animal models of arthri- 
tis, and inhibitors of NOS can reduce arthritis in these con- 
ditions  (6-12).  Moreover,  serum  and  synovial fluid  from 
humans with inflammatory arthritides have increased levels 
of NO  catabolites  (13-15).  Also,  synovial tissue from hu- 
mans  with  inflammatory arthritis  express  NOS2  mRNA 
and protein, and generate NO in vitro (16). 
The  purpose  of the  present  study  was  to  determine 
whether blood mononuclear cells from patients with active 
RA have enhanced expression of NOS2 and enhanced ca- 
pability to produce NO in vitro. We report results of work 
that couples detailed clinical and laboratory rheumatologi- 
cal studies with research laboratory measurements of NOS 
expression and NO production. 
Materials and Methods 
Subjects.  25 patients who met the American Rheumatism As- 
sociation  1987 revised  criteria  for the  classification of RA  (17) 
were recruited  from the  rheumatology outpatient clinics at the 
Duke University  Medical  Center (DUMC).  To be eligible for 
this study, doses ofprednisone (~< 10 mg/d) and nonsteroidal anti- 
inflammatory  drugs  (NSAIDS)  in  RA patients  must have been 
stable for at least 2 wk before entry. Concomitant use of second- 
line drugs such as methotrexate,  gold, sulfasalazine, hydroxychlo- 
roquine,  and  azathioprine  was permitted if the  doses had  been 
stable for at least 4 wk before the study. 20 age (-+5 yr)- and gen- 
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Patients  Controls 
(n =  25)  (n =  20) 
Table 2.  Disease Activity Measures in Patients with RA 
Disease measure  Median (IQR)  Range 
Age (yr)*  58 (14)  56 (23) 
Female gender  17  (68%)  14 (70%) 
Disease duration (yr)  9 (10) 
Subcutaneous nodules  12  (48%) 
Functional class 
I  3  (12%) 
II  15 (60%) 
III  7 (28%) 
Positive P,F  23 (92%) 
Previous second-line drugs  18 (72%) 
Current NSAID users  13 (52%)  2 (10%) 
Current prednisone users  16 (64%)  0 (0%) 
Mean dose (mg/d)  8.5 (5.0) 
Current second-line drug* users  l 8 (72%) 
Current methotrexate users  9 (36%) 
*Values are expressed as the median and interquartile  range for contin- 
uous variables (age, disease duration,  and mean dose),  and as the num- 
ber and percent of subjects for categorical variables. 
r  drugs  include  methotrexate,  hydroxychloroquine,  sul- 
fasalazine, parenteral  gold salts, azathioprine,  and cyclosporine. 
ILF, rheumatoid factor; NSAID, nonsteroidal  antiinflammatory  drug,s. 
der-matched  control  subjects  without  tLA  were  recruited  by 
newspaper  advertising.  The study protocol was  approved by the 
DUMC  Institutional  Review Board.  Informed consent was  ob- 
tained from each subject before participation. 
Patients  and  controls  were  excluded  if they  had  a  coexisting 
chronic  inflammatory  condition,  active  infection,  malignancy, 
cirrhosis,  or  a  serum  creatinine  >2.5  mg/dl.  Pregnant  women 
were excluded because of reports  of elevated NO production  in 
pregnancy  (181. Use  of nitroglycerin,  other  nitrate-containing 
medications,  and  tobacco  products  was  prohibited  during  the 
study. 
Study Design.  Eligible subjects were evaluated in the General 
Clinical Research Center (GCRC) at DUMC. A medical history 
and  physical  examination  were  done  on  adnfission  to  confirm 
subject  eligibility, tLA patients  underwent  a  clinical arthritis  as- 
sesslneut using the t:bllowing disease measures: tender and swollen 
joint count (with a nlaxinmm of 68 tender and 66 swollen joints), 
duration of lnorning stiffness  (minutes), patient assessment of pain 
(10 cm visual analogue scale),  physician and patient global assess- 
lnent  of" disease  activity  (10  cm  visual  analogue  scale),  and  the 
modified Stanford Health Assessment Questionnaire  (HAQ; 19). 
A complete blood count and routine laboratory values, includ- 
ing  serum  creatinine  and  albumiu,  were  obtained  upon  entry. 
The erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CI/,P), indices of KA disease activity, were lneasured in both pa- 
tients and controls. 
Blood ?llom, uMear Cell Pn'panltio,.  40 ml of blood was drawn 
into lithium heparin.  Anticoagulated blood was spun  for 25  mm 
at  150 2,  and  platelet-rich  plasma  was  discarded.  Mononuclear 
cells were then  separated  by centrifhgation  over Ficoll/Hypaque 
Number of tender joints  31  (22)  1>-63 
Number of swollen joints  28 (t7)  5-44 
Morning stiffness  (min)  6(1 (1(15)  (I-1,440 
Physician assessment of disease  41  (39)  3-88 
Patient pain score  46 (42)  11-98 
HAQ score  1.62 (0.88)  0.25-2.88 
ESR (mm/h)*  26 (5l)  5-108 
CFZP  (nag/liter)*  13 (33)  0-96 
Hemoglobulin (g/dl)*  12.9 (1.8)  10.4-16.3 
Sermn albumin (rag/d)*  4.(I (0.4)  3.1-4.6 
*Normal values:  ESR., 0-30;  CP,.P, 0-4;  hemoglobin,  13.5-17.11 for 
males and  11.4-15.2 for females; and serum albumin,  3.5-5.5. 
IQR, interquartile  range. 
(specific gravity =  1.077). Leukocyte-free platelets were prepared 
as  noted  before  (20).  Cytocentrifuge  preparations  of the  cells 
were  analyzed  by  Wright  and  nonspecific  esterase  stains  (2I). 
Cells were then cultured at 5  X  l0  s cells per 6-mm diameter mi- 
crotiter plate well in 0.2 nil of DMEM with 10% heated (56~  3(1 
rain)  nomlal,  pooled  human  serum  for  5  d  without  additives, 
with  recombinant  IFN-y  (500  U/ml;  Genzyme,  Cambridge, 
MA)  alone, with LPS  (1  btg/ml; EscherMlia coil 0128:B12;  Sigma 
Imnmnochemicals,  St.  Louis,  MO)  alone,  or  with  IFN-y  and 
LPS together.  Sonle aliquots of cells were rapidly frozen for sub- 
sequent  analyses.  After 5  d  of culture,  supernatant  media  were 
saved ior nitrite/nitrate  measurement,  and  cell lysates  were pro- 
cessed  for  measurement  of protein,  NOS  enzyme  activity,  and 
NOS2 antigen. 
NTtrite /nitrate,  NO Synthase Enz),me Activit),,  and Antigen A,aly- 
ses.  Since NO is rapidly oxidized to nitrite/nitrate,  stable inor- 
ganic nitrogen oxides, levels of these catabolites have been used as 
an indicator of NO production.  Nitrite/nitrate levels in superna- 
tant media were measured as described (22,  23).  Cellular extracts 
were prepared and analyzed for NOS activity (14-C-L-arginine con- 
version  to  14-C-t-citrulline)  and  antigen  content  by  inmmno- 
blot,  as  described  earlier  (23).  hnnmnoblots  were  done  using  a 
monoclonal  anti-NOS2  antibody  (Transduction  Laboratories, 
Lexington,  KY;  23)  and  the  enhanced  chenfiluminescence  re- 
agents from Amersham (Arlington Heights, ILl. For known  neg- 
ative  and  positive  extracts,  we  used  tmtreated  cells  from  the 
murme  macrophage  cell line J774  and  cells of the murine  mac- 
rophage cell lines J774 and RAW 264 treated with nmrine rlFN-y 
(200 U/roll and LPS (20(I ng/nd) fbr 3 d. 5(I beg protein f~om the 
human and routine cells was used in the individual lanes. A "pos- 
itive immunoblot" for NOS2 was one m  which a clear band  was 
visible at 130-131  kl). 
StatisticalA,all,scs.  Descriptive statistics  are expressed in terms 
of the median and interquartile range for COlmUUOUS  variables and 
as  the  number  and  percent  of subjects  fbr  categorical  variables. 
Comparisons  between  cases  and  controls  were  made  with  thc 
Wilcoxon rank-sum  test tbr continuous variables and with a chi- 
square test of homogeneity for categorical variables. Within-sub- 
ject comparisons used the Quade test (24),  a generalization of the 
Wilcoxon signed-rank test. 
1174  Nitric Oxide and Ikhemnatoid Arthritis Figure 1.  (A) NOS activity in freshly isolated and cultured  mononuclear cells from control  subjects and RA patients. Blood mononuclear cells were 
prepared. Extracts from freshly isolated cells (Fresh) or from cells cultured 5 d with no additions, 1 ~g/ml LPS alone, 500 U/ml IFN-~/alone, or 500 U/nil 
IFN-3' and 1 Dg/ml LPS were assayed for NOS activity (ability to convert L-arginine to t-citrulline).  Assays were done as six replicates for each individ- 
ual subject. Results are shown as medians (horizontal bar), means (circle), the interquartile  range (box), and the lOth to 90th percentile  range (vertical lines). 
There were 20 control subjects and 25 lkA patients. Using the Wilcoxon rank-sum  test, 1LA patients'  NOS activities differed significantly from control 
subjects' NOS activities in the categories Fresh (P <0.003),  No add (P <0.005),  LPS (P <0.002),  IFN-y (P <0.002),  and LPS/IFN-3, (P <0.002).  In 
analyses of cultured  cells, the within-group comparison was significant for RA patients (P <0.00l), but not for control subjects. Pairwise comparisons for 
cells from RA patients  revealed significant differences for treatments  that  included  IFN-y (No add vs.  IFN- T[P <0.003],  and  No add vs. LPS/IFN-3' 
[P <0.003]).  (/3) Nitrite/nitrate  production  by cultured mononuclear  cells from normal subjects and RA patients. Blood mononuclear  cells were prepared 
and cultured  5 d with no additions,  1 Ixg/ml LPS alone, 500 U/ml IFN-'/alone, or 500 U/nil IFN-',/and 1 l,  tg/ml LPS. Supernatant  media were then 
measured for nitrite/nitrate.  Assays were done as six replicates for each individual subject. Results are shown as medians (horizontal bar), means (circle), the 
interquartile  range  (box), and the lOth to 90th percentile  range (vertical lines). There were 20 control  subjects and 25 RA patients.  Using the Wilcoxon 
rank-sum  test,  ILA patient's  nitrite/nitrate levels differed significantly from  control  subjects'  nitrite/nitrate levels in the categories LPS (P <0.01)  and 
LPS+IFN-y (P <0.02). Within-group comparison was significant for control subjects (P <0.02), but not for 1LA patients. Pairwise comparisons for cells 
from control  subjects revealed sibmificant differences for No add vs. LPS (P <0.02) and LPS vs. IFN-3' [P <0.003]).  (C) Immunoblot analysis ofmono- 
nuclear cells from normal  controls and lkA patients for NOS2 expression. Blood mononuclear cells were isolated, and extracts were analyzed for NOS2 
antigen  content using an NOS2-specific  mouse monoclonal anti-NOS2 antibody.  The NOS2 antigen has a molecular  mass of~130 kD.  Extracts from 
the nmrine macrophage  cell line cells J774 and RAW 264 were used as negative and positive controls. 40 Ixg of protein  from the extracts were used in 
each lane. Parallel gels and blots done using isotype-specific control Ig showed no reactivity. J, J774 control;J+, J774 cells cultured with LPS +  IFN-y; 
r+, RAW 264 cells cultured  with LPS +  IFN-y; R1-5,  samples from five separate 1LA patients; N1-5, samples from five separate normal  (control) sub- 
jects. While only 3 of 20 samples from controls were positive,  19 of 25 samples from P,A patients were positive. 
Results 
Patient  Characteristics.  25  tLA  patients  and  20  healthy 
controls  were  eligible for  the  study.  Characteristics  of the 
patients  and  controls are described in Table  1.  ILA patients 
generally had long-standing,  severe disease, as evidenced by 
their  use  of multiple  second-line  drugs,  and  the  relatively 
high  prevalence  of serum  rheumatoid  factor positivity and 
subcutaneous  nodules.  Most  of the  RA  patients  were  re- 
ceiving multiple  arthritis  medications.  Approximately  half 
of the ILA patients  were taking an NSAID, while only 2  of 
the  20  controls  were  taking a  medication  from this  class of 
antiinflammatory  agents.  Of the  25  RA  patients,  18  (72%) 
and  16  (64%) were receiving concomitant second-line drug 
and  low  dose  prednisone  therapy,  respectively.  Despite 
treatment  with  these  agents,  the  1LA  patients  exhibited 
tnoderate  disease  activity,  as  shown  by  high  tender  and 
swollen joints  counts,  long durations  of morning  stiffness, 
moderately  high levels of functional  disability,  as measured 
by  the  HAQ,  and  elevated levels of the  acute  phase  reac- 
tants ESP, and  CtLP  (Table 2). 
NOS  Enzyme  Activity  in  Blood  Mononuclear  Cells. 
NOS  activity was measured in freshly isolated and cultured 
cells  from  tLA  patients  and  controls.  Freshly  isolated  ceils 
from  1LA  patients  had  significantly  higher  levels  of NOS 
activity than  did the cells from control subjects  (P <0.004) 
(Fig.  1  A).  The  numbers  of monocytes  in  the  freshly  iso- 
lated  mononuclear  ceils  were  essentially  identical  in  the 
two groups:  59  (21)%  (median  [interquartile  range])  in RA 
patients,  and  55  [191%  in  control  subjects.  It is very likely 
that the bulk of the NOS  activity was present in monocytes 
and not lymphocytes or platelets.  Analysis of leukocyte-free 
platelets  demonstrated  that  <9%  of the  total  NOS  activity 
could be attributed  to  the small numbers  of platelets in the 
preparations.  Although  human  EBV  infected  lymphocytes 
may have very small amounts  of NOS  activity (25),  normal 
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clusion of 2 mM NQmonomethyl-r-arginine in the NOS 
assay reduced the  conversion of L-arginine to t-citrulline 
by >90%. 
To assess the responsiveness of blood mononuclear cells 
to immune stimulation, isolated cells from controls and RA 
patients  were  cultured  without  additives,  with  LPS  alone, 
IFN-'y alone, or the combination for 5 d. NOS activity in 
the cultured, untreated cells from RA patients was twofold 
greater than that in controls (Fig.  1 A), indicating that the 
cells  from  RA  patients  retained  increased  NOS  activity, 
even after 5 d  of in vitro culture.  In agreement with our 
previous observations (23),  treatment of cells from controls 
with LPS alone, IFN-'y alone, or the combination in vitro 
did not augment NOS  activity. However, cells from RA 
patients cultured in vitro with  IFN-'y alone or IFN-w  + 
LPS exhibited significantly increased NOS activity (Fig.  1 
A).  Comparable  to  the  increases in  NOS  activity in RA 
cells,  supernatant media from the RA  cells  cultured with 
LPS or LPS  +  IFN-y contained more nitrite/nitrate than 
did those from control subjects (Fig.  1 /3). 
NOS Antigen Expression.  Freshly isolated cells from each 
control subject and RA patient were analyzed by immuno- 
blot for NOS2 antigen expression. Cell lysates from 19 of 
the 25 RA patients contained a protein (130-131 kD) that 
reacted with the anti-NOS2--specific antibody, while only 
3  of  20  from  controls  displayed  the  antigen  on  blot 
(P <0.0001).  There  was  no  reaction  with  an  isotype- 
matched (IgG2a) control Ig. Fig.  1 C shows examples from 
controls and RA patients. 
Relationship between NOS Activity,  Medications, and Disease 
Measures.  RA  patients  had increased NOS  activity rela- 
tive to control subjects, despite concomitant use of medica- 
tions that might inhibit this enzyme. The 13 patients taking 
NSAIDS had lower NOS  activity (pmol citrulline/mg) in 
their  freshly isolated  cells  (27  [15],  median  [interquartile 
range])  than  did the  12  patients  not  taking  NSAIDS  (39 
[32]). The 16 patients receiving prednisone had comparable 
NOS activity (31 [26]) to the 9 patients not receiving pred- 
nisone (32 [55]).  NOS activity in the 9 RA patients taking 
methotrexate (39 [33]) was higher than that for the  16 pa- 
tients  not  taking  methotrexate  (31  [22]).  Because  of the 
complexity of the drug regimens (several patients were tak- 
ing multiple medications) and small numbers of subjects in 
the different groups, these results were not analyzed statisti- 
cally. 
NOS activity of freshly isolated cells was  investigated as 
correlates  of traditional  clinical  and  laboratory indices  of 
disease  activity. No significant relationship was  found be- 
tween NOS activity and the HAQ score, physician and pa- 
tient global assessment  of disease activity, patient pain scale, 
or levels of the acute phase reactants ESR and CRP. NOS 
activity of freshly isolated blood cells,  however, was  posi- 
tively correlated with  the  tender joint  counts  (r  =  0.48) 
and swollen joint counts (r =  0.47) (P <0.02 for each), in- 
dicating  a  possible  relationship  between  blood  cell  NOS 
activity and the extent of  joint inflammation. 
Discussion 
Our study documents that mononuclear blood cells from 
RA patients are activated for systemic NO overproduction. 
Patients  have increased NOS  enzyme activity and NOS2 
antigen  in  freshly isolated blood mononuclear cells.  Fur- 
thermore, when cultured in vitro, cells from RA patients 
respond to LPS, IFN-% or the combination of both by in- 
creasing their levels of NOS activity and NO  production, 
while cells from controls do not. Our data provide new in- 
formation  indicating  the  potential  importance  of NOS2 
and NO in the pathogenesis of RA, and they raise the pos- 
sibility that excess NOS2  expression and NO  production 
could be targeted for therapy in humans with RA. 
Although  previous studies  of blood monocytes in  RA 
patients have noted systemic activation for the generation 
of reactive  oxygen species  generation,  prostanoids,  IL-I, 
TNF, and neopterin (27-29), our work is the first to dem- 
onstrate systemic activation of blood mononuclear cells in 
this disease  for NOS expression and NO production. NO 
is an important inflammatory mediator in  nonhuman ani- 
mal  models  of inflammatory arthritis;  these  include  adju- 
vant  arthritis,  collagen-induced  arthritis,  and  spontaneous 
arthritis  in  autoimmune  MRL-lpr/lpr  mice  (6,  11,  30). 
Likewise, NO participates in the pathogenesis of spontane- 
ous myositis in the SJL mouse (31).  NO has been reported 
to be  increased  in  the  synovial fluid and  sera  of patients 
with RA  (13,  15,  32); however, some of these studies are 
difficult to evaluate because the subjects' oral intake of ni- 
trite and nitrate (NO catabolites measured by the investiga- 
tors)  was  not limited and quantitated.  Kaur and Halliwell 
showed increased levels of nitrotyrosine (a product result- 
ing from peroxynitrite action) in serum and synovial fluid 
from arthritis patients  (14).  Investigators have recently re- 
ported that synovial tissues from patients with RA and os- 
teoarthritis produce NO in vitro, and express NOS2 mRNA 
(reverse transcription-PCR) and protein (immunoblot and 
immunohistology).  NOS2  was  associated  primarily  with 
CD14 + cells (mononuclear phagocytes; 16). In RA, blood 
monocytes are recruited to synovial tissues.  Recently emi- 
grated  monocytes may be  activated for  NOS  expression 
and  NO  production in  the  synovium  (16).  Also,  mono- 
cytes activated for NOS expression and NO production in 
the circulation may emigrate to the synovium where they 
may initiate and propagate inflammation. 
NO  has  many actions that are appropriate for a proin- 
flammatory agent. It is made by numerous cell types in sites 
of inflammation,  and it increases blood flow and vascular 
permeability. NO has cell and tissue-destructive abilities;  it 
can also induce cyclooxygenase, cause pain, destroy certain 
protease inhibitors, and enhance IL-1, TNF, and NADPH 
oxidase activities in myeloid cells (6,  33).  NO production 
may be augmented by several substances,  including cyto- 
kines,  growth  factors,  immune  complexes,  and  bacterial 
products. Since superoxide (02-) may convert NO to per- 
oxynitrite  (a  potent  proinflammatory molecule  [34,  35]), 
coincident production of NO and O~- may further amplify 
the inflammatory state.  In  the joint,  several cell types can 
1176  Nitric Oxide and Rheumatoid Arthritis produce NO--mononuclear phagocytes, chondrocytes, en- 
dothelial  cells,  and  possibly others.  Mononuclear  phago- 
cytes and  chondrocytes are the most likely sources in  the 
joint. Human articular chondrocytes produce relatively high 
levels of NO in response to cytokines (11, 36, 37). If NO is 
a vital mediator of joint inflammation in RA, then block- 
ing  NO  production  by  NOS2-specific  inhibitors  and 
blocking NO  effects by NO  quenchers may have therapeu- 
tic roles in RA. 
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